SAN DIEGO, Calif., April 14, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chains, announced today today that its subsidiary Kannaway® achieved its highest revenue month in company history at its South African division in March 2022.
The cannabis industry in Africa is growing rapidly, becoming one of the company’s key international growth markets, and is expected to become a $7 billion market by 2023. Reach and Markets points out that the South African cannabis/cannabidiol (CBD) market is expected to experience a CAGR of 28.4% Between 2022 and 2026.
“So far, 2022 has been a truly remarkable year for sales in South Africa,” said Medical Marijuana, Inc. CEO Blake Schroeder. “We are excited about our very rapid growth in the market and look forward to continued growth not only in South Africa, but also our expansion across the continent as cannabis becomes legally accepted and free access continues to grow. ‘be newly activated.’
To learn more about Kannaway®, please visit the company online at https://www.kannaway.com/.
Kannaway® is a network sales and marketing company specializing in the sale and marketing of hemp-based botanical products. Kannaway® currently hosts weekly online sales meetings and conferences across the United States, providing unique insight and opportunity for sales professionals who want to become successful leaders in the sale and marketing of botanicals. of hemp.
About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct non-psychoactive cannabinoid business units: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in providing the highest quality non-psychoactive legal cannabis products derived from industrial hemp; and a clinical research and development sector for cannabinoid-based botanical drugs led by its pharmaceutical investment companies and partners, including AXIM® Biotechnologies, Inc.. and Neuropathix. Medical Marijuana, Inc. was named one of the top CBD producers by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina and Paraguay and is a leader in developing international markets. The company’s flagship product Genuine Scientific Hemp Oil has been used in several successful clinical studies in Mexico and Brazil to understand its safety and effectiveness.
Medical Marijuana, Inc. is headquartered in San Diego, CA and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To view the Medical Marijuana, Inc. corporate video, Click here.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor created by these articles. This document contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. These forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to differ materially from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Medical Marijuana, Inc. does not sell or distribute products that violate the US Controlled Substances Act.
Public relations contact:
Contact with Investor Relations:
T. (858) 283-4016
#Medical #Marijuana #Subsidiary #Kannaway #Celebrates #Revenue #Month #Company #History #South #Africa #Division #March